A P1 Safety Study of AV-101 for Chronic Neuropathic Pain
The Bottom Line: The primary safety and tolerability endpoints of the P1 program were met. Let’s see how the P2 study progresses for the treatment of pain. VSTA closed at $0.79 on 1/22/13 with increasing volume of 13.5 K shares from the past days of 0. Look for VSTA to open up for the day!
I just added $VSTA at $.60 after someone convinced me of the massive upside we could see here on any one of a few approvals. I do not know the Other medical companies pursuing these novel candidate solutions, but we have a HUGE upside at this price if we only partially succeed.